CheMatech will be present at TERACHEM 2022, Septembre 14-17.
Looking froward to meeting you in Bressanone!
The discovery and development of theranostics requires multiple highly secialized skills which have been combined in an managed alliance with COVALAB, Oncodesign, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft serving a premium solution in Nuclear Medicine
Learn more about the innovative platform DRIVE-MRT in this Webinar.
Register today ➡️
CheMatech (Dijon, France), the European leader in the design, synthesis and supply of chelating agents, ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing in the development and production of custom antibodies and ABX-CRO (Dresden, Germany), the globally leading full-service CRO for molecular imaging and radiotherapy, today announce their partnership. This strategic collaboration will launch the DRIVE™-MRT (Molecular RadioTherapy) solution. This innovative, premium service offer for therapeutic development is unique in nuclear medicine; it encompasses the full drug discovery process of theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to the design and management of clinical trials.
CheMatech is very excited to launch its new product (+)-RESCA-TFP an efficient chelators for Al18F radiolabeling. This product is also available in GMP quality.
CheMatech will be present at the Third International Symposium on Technetium and other Radiometals in Chemistry and Medicine TERACHEM 2018, September 26-29, 2018, in Bressanone, Italy. We will be more than happy to welcome you to our booth and to present you our new products and services.